Loading...

ALLO ALLOGENE THERAPEUTICS INC Operational Disruptions 8-K Filing

LLGN

LL

ALLOGENE THERAPEUTICS INC

(ALLO)

2023 8-K

Summary

Summary

Patent Infringement Case

Financial Update

Product Expansion

Financial Statements

Financial Results

Collaboration Expansion

Management Departure

Trial Enrollment Discontinued

Financial Results

Financial Results Announcement

Appointment of Principal Ac...

Merger of Equals

Financial Results Announcement

Financial Results Announcement

Accounting Restatement

Agreement with Notch Therap...

Collaboration Agreement

Safety Review Data

Financial Results Announcement

Appointment of CFO

Appointment of Executive Vi...

Financial Update

Data Presentation

Annual Meeting Results

Resignation of CFO

Data Presentation

Financial Update

Management Changes

Other Special Situation

Financial Results Announcement

Resignation of EVP

External Links:

Allogene Therapeutics presented updated data from Phase 1 trials of ALLO-501/501A in CAR T-naive patients with large B-cell lymphoma, showing positive response rates and tolerability.

AI Assistant

ALLOGENE THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.